Abstract
Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. We explored the predictive value of pre-biopsy PLRs for CSPCa using our large-cohort database. Consecutive men with serum prostate-specific antigen (PSA) levels of ≥ 3.0 ng/mL or abnormal digital rectal examination (DRE) findings and who underwent prostate biopsies were included in the study. There was no significant difference in the pre-biopsy PLR between men with benign disease, clinically insignificant prostate cancer (CISPCa), and CSPCa. Only the subset of CSPCa patients with serum PSA levels of < 10 ng/mL showed lower PLRs than those with benign disease or CISPCa. In the entire patient cohort, multivariate analyses revealed that older age, diabetes mellitus, DRE abnormalities, higher serum PSA levels, and smaller prostate volume were predictors of CSPCa. However, the pre-biopsy PLR was not a significant predictor of CSPCa at the prostate biopsy in the entire patient cohort or the subset of patients with serum PSA levels of < 10 ng/mL. In summary, the pre-biopsy PLR is not an independent predictor of CSPCa at the prostate biopsy, regardless of the serum PSA level.
Highlights
Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies
A recent meta-analysis showed that systemic inflammatory markers such as the platelet-to-lymphocyte ratio (PLR), which could be calculated from the complete blood count (CBC), were associated with the prognosis of men with P Ca9
Comparison of patient characteristics according to pre‐biopsy serum prostate-specific antigen (PSA) levels
Summary
Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. A recent meta-analysis showed that systemic inflammatory markers such as the platelet-to-lymphocyte ratio (PLR), which could be calculated from the complete blood count (CBC), were associated with the prognosis of men with P Ca9 In this context, a minority of studies of small or medium-sized cohorts have tested the predictive role of PLR in detecting clinically significant cancers at the time of prostate biopsies but reported conflicting results[10,11,12,13,14]. Cancers (CSPCa) at the time of the standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx), currently the reference standard for the diagnosis of PCa, using our large cohort data
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.